Study #2024-1726
Phase 1 trial of BTM-3566 in relapsed/refractory mature B Cell Lymphomas.
MD Anderson Study Status
Enrolling
Treatment Agent
BTM-3566
Description
The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are: What are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. how well does it slow or stop disease progression)? Participants will: Take BTM-3566 in 14-day periods with 7 days of dosing followed by 7 days of no dosing Visit the clinic regularly for checkups and tests Keep a diary of their dosing and weight
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, B-Cell
Study phase:
Phase I
Physician name:
Michael Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-929-4217
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.